Active infection requiring intravenous (IV) antibiotics
Active infection requiring intravenous antibiotics within 1 week of study enrollment (day 1).
Active infection requiring intravenous antibiotics at cycle 1 day 1
Active systemic infection requiring intravenous antibiotics within 2 weeks of treatment start
Patients with any unstable medical issue (including cardiac issues as above, active treatment for symptomatic pulmonary embolism, cerebrovascular accident [CVA], renal or hepatic insufficiency, active infection/sepsis requiring intravenous [IV] antibiotics)
Ongoing or active infection; the requirement for intravenous (IV) antibiotics is considered active infection
Ongoing active infection; the requirement for intravenous (IV) antibiotics is considered active infection
Active infection (infection requiring intravenous antibiotics)
Active infection requiring intravenous (IV) antibiotics within 14 days before Day 1, Cycle 1
Active infection requiring intravenous antibiotics at week 1 day 1
Active serious infection not controlled by oral or intravenous antibiotics
Clinically significant active infection requiring intravenous antibiotics (=< 14 days prior to registration)
Active infection requiring intravenous antibiotics (must be completed prior to registration)
Infection requiring intravenous antibiotics that was completed < 1 week of study enrollment (day 1) with the exemption of prophylactic antibiotics for long line insertion or biopsy
Active infection (requiring oral or intravenous antibiotics or antiviral therapy).
Active serious infection not controlled by oral or intravenous antibiotics.
Patients with active systemic infections requiring intravenous antibiotics within 1 week prior to enrollment
Active infection requiring intravenous antibiotics (antibiotics should have been completed prior to registration)
Active serious infection not controlled by oral or intravenous antibiotics.
Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization.
Clinically significant active infection requiring intravenous antibiotics =< 14 days prior to registration
Any uncontrolled active systemic infection requiring intravenous (IV) antibiotics
Active infection requiring intravenous antibiotics
Evidence of ongoing or active infection requiring intravenous antibiotics;
Active infection requiring intravenous antibiotics within 7 days before enrollment
Active infection requiring intravenous antibiotics at the time of registration
Patients must be free of systemic infection requiring intravenous (IV) antibiotics at the time of registration; patients must be off IV antibiotics for at least 7 days prior to registration
Unstable systemic disease in the opinion of the treating physician, for example active infection requiring intravenous (IV) antibiotics
Serious active infection requiring intravenous (IV) antibiotics
Patients must be free of systemic infection requiring intravenous (IV) antibiotics at the time of registration; patients must be off IV antibiotics for at least 7 days prior to registration
Patients should be free of active infection requiring intravenous antibiotics
Active serious infection not controlled by oral or intravenous antibiotics
Patients must be free of systemic infection requiring intravenous (IV) antibiotics at the time of registration; patients must be off IV antibiotics for at least 7 days prior to registration
Active infection requiring oral or intravenous antibiotics
Patients with active chronic or current infections requiring oral or intravenous antibiotics are NOT eligible for enrollment to the study until resolution of the infection and completion of therapeutic antibiotics
Active clinically serious infection requiring intravenous antibiotics at the time of study entry (CTCAE Grade 2)
Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization.
Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization
Serious infection requiring treatment with intravenous antibiotics at the time of study entrance, or an infection requiring intravenous therapy within 7 days prior.
Serious infection requiring hospitalization or intravenous (IV) antibiotics within 14 days prior to enrollment
Active infection requiring intravenous antibiotics
At least 7 days beyond any infection requiring intravenous antibiotic use (Oral\n             antibiotics may be administered prophylactically as clinically indicated)
Patients have an active infection and require intravenous (IV) or oral antibiotics
Receipt of intravenous antibiotics for infection within 7 days prior to enrollment
Patients with active infection and requiring intravenous (IV) or oral antibiotics
Serious active infection requiring intravenous (i.v.) antibiotics at enrollment
Active systemic infections requiring intravenous antibiotics
Patients must not have uncontrolled active systemic infection requiring intravenous antibiotics
Patients with active systemic infection requiring intravenous antibiotics
Serious active infection requiring intravenous antibiotics and/or hospitalization at study entry
Any infection requiring ongoing intravenous antibiotics for management
Patient has evidence of a serious active infection (e.g., infection requiring treatment with intravenous antibiotics).
Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization
Active (acute or chronic) or uncontrolled severe infections requiring intravenous antibiotics
Have an ongoing or active infection. The requirement for intravenous (IV) antibiotics is considered active infection.
Serious infection requiring treatment with intravenous antibiotics at the time of study entrance, or an infection requiring intravenous therapy within 7 days prior to the first dose of study treatment.
Receipt of intravenous (IV) antibiotics for infection within 7 days prior to enrollment into the study
Patients with active infection and requiring intravenous (IV) or oral antibiotics
Infection requiring intravenous antibiotics within 14 days before the first dose of study drug
Concurrent severe and/or uncontrolled medical disease including, but not limited to, ongoing or active infection requiring intravenous antibiotics, bowel obstruction
Concurrent severe and/or uncontrolled medical disease including, but not limited to, ongoing or active infection requiring intravenous antibiotics
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring intravenous antibiotics
Serious, active infections requiring treatment with intravenous (IV) antibiotics
Active infection, uncontrolled with intravenous antibiotics
Patients with active infection requiring intravenous (IV) antibiotics within 2 weeks of registration
Active systemic infections requiring intravenous antibiotics
Active serious infection not controlled by oral or intravenous antibiotics
Patients have an active infection and require intravenous (IV) or oral antibiotics
Active infection requiring intravenous antibiotics
Active infection requiring intravenous (IV) antibiotics
Any uncontrolled active systemic infection that requires treatment with intravenous (IV) antibiotics
Presence of an infection that requires intravenous antibiotics
Active infection requiring intravenous antibiotics.
Current acute infection requiring intravenous antibiotics
Uncontrolled medical illness such as infection requiring intravenous antibiotics
Active infection requiring intravenous (IV) antibiotics
Known active infection requiring intravenous (IV) or oral anti-infective treatment
History of any infection requiring hospitalization or intravenous antibiotics within 2 weeks before enrollment.
The patient has received intravenous administration of antibiotics within 2 weeks prior to first study treatment or oral antibiotics within 1 week prior to first study treatment.
Active systemic infections requiring intravenous antibiotics
Use of intravenous antibiotics within the last 6 months
Serious concomitant medical condition that could interfere with the conduct of the clinical trial, such as unstable angina, renal failure requiring hemodialysis, or active infection requiring intravenous (IV) antibiotics
Diagnosis of an infection requiring intravenous (IV) antibiotics 14 days prior to registration
Active systemic infection requiring ongoing intervention, including but not limited to oral and intravenous antibiotics, anti-fungals, anti-parasites, anti-virals
Active infection requiring oral or intravenous antibiotics
The participant has an active infection (requiring intravenous [IV] antibiotics), including tuberculosis.
Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or intravenous (IV) antibiotics within 2 weeks prior to randomization; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or intravenous (IV) antibiotics within 14 days prior to randomization; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Patients must not have an active infection requiring oral or IV antibiotics within 14 days prior to registration; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Treatment with oral or intravenous (IV) antibiotics within 2 weeks prior to Day 1 of Cycle 1
Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment, except prophylactic antibiotics
Received oral or intravenous (IV) antibiotics within 2 weeks prior to Cycle 1, Day 1. Participants receiving prophylactic antibiotics (for prevention of a urinary tract infection chronic obstructive pulmonary disease) are eligible
Received therapeutic oral or IV antibiotics within 2 weeks prior to Day 0;
Therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to first day of study treatment:\r\n* Patients receiving prophylactic antibiotics (eg, to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible
GENERAL: Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1.\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible.
Treatment with oral or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1
Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or IV antibiotics within 2 weeks prior to start of study treatment.\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible.
Received therapeutic oral or IV antibiotics within 2 weeks prior to first day of study treatment:\r\nPatients receiving prophylactic antibiotics (eg, to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible
Received oral or IV antibiotics for an infection within 2 weeks prior to the first study treatment. Subjects receiving prophylactic antibiotics are eligible
Treatment with therapeutic oral or IV antibiotics within 14 days prior to initiation of study treatment; patients receiving prophylactic antibiotics (e.g. for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or IV antibiotics within 2 weeks prior to study treatment; but patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1 a) Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Oral or IV antibiotics within 2 weeks prior to enrollment
Received therapeutic oral or IV antibiotics within 1 week prior to cycle 1 day 1\r\n* Subjects receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or to prevent chronic obstructive pulmonary disease exacerbation) are eligible
Received oral or IV antibiotics =< 2 weeks prior to cycle 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Oral or IV antibiotics within 2 weeks prior to enrollment
Oral or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1
Patients who have received oral or IV antibiotics within 2 weeks before initiation of study treatment; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1 (Patients receiving prophylactic antibiotics [e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease] are eligible.)
Received oral or IV antibiotics within 2 weeks prior to week 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received therapeutic oral or IV antibiotics within 2 weeks prior to first dosing.
Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment; patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study
Received therapeutic oral or IV antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Therapeutic oral or IV antibiotics within 2 weeks prior to cycle 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or to prevent chronic obstructive pulmonary disease exacerbation) are eligible
Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received therapeutic oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1
Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1 for treatment of active infection (patients receiving prophylactic antibiotics [e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease] are eligible)
Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to the first dose of study treatment
Received IV antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Received therapeutic oral or IV antibiotics within 4 weeks prior to Cycle 1, Day 1 (except for tumor fever)
Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to first day of study treatment; patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible
Received oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1
Received oral or IV antibiotics within 14 days prior to Day 1
Active infection or chronic infection requiring chronic suppressive antibiotics
Active infection requiring treatment with antibiotics
Patients must not have a serious intercurrent illness, including ongoing or active infection requiring parental antibiotics
Active infection or chronic infection requiring chronic suppressive antibiotics.
Active infections requiring antibiotics, physician monitoring or recurrent fevers >100.4?F (38.0?C) associated with a clinical diagnosis of active infection
Active infection requiring IV antibiotics at day 1 of cycle 1
Active infection requiring IV antibiotics within 2 weeks of study dose
No active infection requiring antibiotics
Active infection requiring antibiotics
Active infection requiring iv antibiotics at day 1 of cycle 1
EXCLUSION - PROCUREMENT: Active infection requiring antibiotics
Active infection requiring IV antibiotics on Cycle 1, Day 1
If they have a major systemic infection requiring antibiotics 72 hours or less prior to the first dose of study drug
Patients should not have any evidence of active or uncontrolled infection requiring treatment with antibiotics
Currently using antibiotics and/or anti fungal agent (however, topical antibiotics are permitted).
Active infection requiring systemic antibiotics or antifungals within 7 days prior to first dose of study drug; exception: tetracycline family antibiotics (tetracycline, doxycycline, minocycline) administered for the management of cetuximab-related rash may be continued per the investigatorâ€™s judgment
Active infection requiring the use of systemic antibiotics
Participant has an active infection requiring IV antibiotics
Active infection requiring systemic antibiotics within 2 weeks prior to cycle 1, day 1; prophylactic short-term antibiotics will be allowed
Has an active infection requiring systemic therapy with IV antibiotics
Presence of an serious illness, uncontrolled illness, or active infection requiring IV antibiotics.
Active infection or chronic infection requiring chronic suppressive antibiotics
Have active infection requiring antibiotics
Has an active infection requiring systemic antibiotics within 10 days of registration
Patients should not be on antibiotics for any infection but post operative antibiotics are allowed if used prophylactically but should be completed prior to starting RT
Known HIV-1 or any active infection requiring IV antibiotics
Major systemic infection requiring antibiotics 72 hours or less prior to first dose of study drug
Active infection requiring IV antibiotics 7 days before enrollment
Patients must not have an active major systemic infection requiring systemic antibiotics 72 hours or less prior to the first dose of study drug
Patients should be free of active infection requiring antibiotics
Active infection requiring systemic therapy with IV antibiotics
Active infection or chronic infection requiring chronic suppressive antibiotics.
Active infection requiring antibiotics
Active infection not adequately responding to appropriate antibiotics (i.e. ongoing temperatures of >= 38 degree Celsius)
Active infection requiring antibiotics
Active infection requiring treatment with systemic antibiotics or systemic anti-fungal agents
Active infection or chronic infection requiring chronic suppressive antibiotics.
Treated with antibiotics for infection within one week prior to study entry.
If they have a major systemic infection requiring antibiotics 72 hours or less prior to the first dose of study drug
Treatment with antibiotics within 2 weeks (14 days) of dosing
Subjects with an active infection requiring antibiotics or at an increased risk of latent infection that may affect safe study participation
Subjects with active infection requiring IV antibiotics within 2 weeks of study enrollment (day 1) are excluded
Active infection-must be afebrile and off antibiotics
Participants with an active infection requiring antibiotics are excluded (a positive screening urinalysis may be repeated)
Uncontrolled infection requiring active treatment (systemic antibiotics, anti-virals, or anti-fungals) within 14 days
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment unless the patient is felt to have fully recovered and any antibiotics that are continued are either beta lactam antibiotics or are specifically allowed on study
Active infection or chronic infection requiring chronic suppressive antibiotics
Evidence of any active infection requiring hospitalization or IV antibiotics within 2 weeks prior to study enrolment.
Active infection, or chronic infection requiring chronic suppressive antibiotics.
Active pulmonary infection not responsive to conventional antibiotics
Any known HIV infection or AIDS or any concurrent infection requiring IV antibiotics
Has an active infection requiring systemic antibiotics within 7 days of registration
Active infection or antibiotics within 48 hours prior to study
Active infection within the 14 days prior to randomization requiring systemic antibiotics
Active infection requiring treatment with IV antibiotics or hospitalized for treatment of an active infection in 4 wks prior to starting dose of AMG 592.
Presence of acute active infection requiring antibiotics
Serious active infection requiring i.v. antibiotics and/or hospitalization at study entry
Patients with an active infection requiring antibiotics
Active infection not adequately responding to appropriate antibiotics (i.e. ongoing temperatures of >= 38 degree Celsius)
Patients should be free of active infection requiring antibiotics
Uncontrolled infection requiring ongoing antibiotics
Current severe, uncontrolled systemic disease including an ongoing, active infection requiring treatment with antibiotics
Active infection involving IV antibiotics within 2 weeks prior to C1D1
Active uncontrolled serious infection or sepsis at study enrollment; patients receiving antibiotics for infections that are under control may be included in the study
Active infection involving IV antibiotics within 2 weeks prior to C1D1
Patients should not have any evidence of active or uncontrolled infection requiring treatment with antibiotics
Has an active infection requiring antibiotics
Ongoing or active infection requiring parental antibiotics on Day 1
Known active infection requiring antibiotics within 7 days of the start of treatment (day 0)
Ongoing or active infection requiring IV antibiotics
Active infection requiring antibiotics
Treatment with antibiotics within 2 weeks (14 days) of dosing.
Has an active infection requiring systemic antibiotics.
Active infection requiring antibiotics
Ongoing or active infection requiring antibiotics;
Has an active infection requiring systemic antibiotics
Active infection requiring IV antibiotics
Active infection requiring antibiotics
Active infection requiring antibiotics
Active infection requiring antibiotics
Active infection requiring IV antibiotics within 2 weeks prior to screening
Active infection requiring iv antibiotics
Uncontrolled infection requiring systematic antibiotics within 14 days before the first dose of study drug
Has uncontrolled infection requiring systematic antibiotics
Active infection requiring (IV) antibiotics within 2 weeks of study enrollment
Active infection requiring IV antibiotics
Any infection requiring antibiotics within the past 2 weeks.
Serious infection requiring antibiotics
Pneumonia requiring antibiotics at the time of study enrollment
Patients with a previous or current line infection are ineligible until 14 days after the completion of antibiotics
Active infection requiring antibiotics
No use of antibiotics in the previous 3 months; or current regular use of antibiotics
Patients should be free of active infection requiring antibiotics
A non?urologic bacterial infection requiring active treatment with antibiotics
Patients with active and/or uncontrolled infections or who are still recovering from an infection\r\n* Actively febrile patients with uncertain etiology of febrile episode\r\n* All antibiotics should be completed at least 1 week (7 days) prior to collection\r\n* No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics\r\n* Note: Use of antibiotics for pre-operative prophylaxis is not an exclusion
The participant has an active infection (requiring I.V antibiotics), including tuberculosis.
